China Biologic to Report Second Quarter 2014 Financial Results
BEIJING, July 29, 2014 /PRNewswire/ — China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second quarter 2014 financial results on Tuesday, August 5, 2014 after the market closes.
The Company’s management will hold a conference call at 8:00 a.m. ET on Wednesday, August 6, 2014, which is 8:00 p.m., Beijing Time on August 6, 2014, to discuss second quarter 2014 results. Listeners may access the call by dialing:
US: 1 877 870 4263
International: 1 412 317 0790
Hong Kong: 800 905 945
China: 400 120 1203
Passcode: China Biologic Products Inc.
A telephone replay will be available one hour after the conclusion of the conference call through 9:00 a.m., Eastern Time on August 13, 2014. The dial-in details are:
US: 1 877 344 7529
International: 1 412 317 0088
A live and archived webcast of the conference call will be available through the Company’s investor relations website at http://chinabiologic.investorroom.com/.
About China Biologic Products, Inc.
China Biologic is a leading plasma-based biopharmaceutical company in China. The Company’s products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi’an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China. For additional information, please see the Company’s website www.chinabiologic.com .
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191